v3.26.1
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2024 $ 102 $ 16,491,504 $ (9,757,160) $ 6,734,446
Balance, shares at Dec. 31, 2024 1,021,110      
Common stock issued pursuant to public offering $ 2 3,999,998 4,000,000
Common stock issued pursuant to public offering, shares 17,778      
Common stock issued pursuant to consulting agreement 543,520 543,520
Common stock issued pursuant to consulting agreement, shares 3,040      
Vested restricted stock granted to consultants $ 2 2,875,558 2,875,560
Vested restricted stock granted to consultants, shares 19,722      
Vested restricted stock granted to directors $ 17 24,278,741 24,278,758
Vested restricted stock granted to directors, shares 167,250      
Vested restricted stock granted to employees 75,584 75,584
Vested restricted stock granted to employees, shares 300      
Offering costs (1,598,196) (1,598,196)
Net loss (32,430,903) (32,430,903)
Balance at Mar. 31, 2025 $ 123 46,666,708 (42,188,063) 4,478,768
Balance, shares at Mar. 31, 2025 1,229,200      
Balance at Dec. 31, 2024 $ 102 16,491,504 (9,757,160) 6,734,446
Balance, shares at Dec. 31, 2024 1,021,110      
Net loss       (39,103,367)
Balance at Jun. 30, 2025 $ 126 49,765,656 (48,860,527) 905,255
Balance, shares at Jun. 30, 2025 1,262,896      
Balance at Mar. 31, 2025 $ 123 46,666,708 (42,188,063) 4,478,768
Balance, shares at Mar. 31, 2025 1,229,200      
Vested restricted stock granted to employees 354,563 354,563
Vested restricted stock granted to employees, shares 889      
Offering costs (499,349) (499,349)
Net loss   (6,672,464) (6,672,464)
Common stock issued pursuant to equity purchase agreement $ 2 1,149,415 1,149,417
Common stock issued pursuant to equity purchase agreement, shares 23,101      
Issuance of commitment shares under equity purchase agreement 594,320 594,320
Issuance of commitment shares under equity purchase agreement, shares 3,040      
Common stock issued in partial settlement of seller’s note $ 1 1,499,999 1,500,000
Common stock issued in partial settlement of seller's note, shares 6,667      
Balance at Jun. 30, 2025 $ 126 49,765,656 (48,860,527) 905,255
Balance, shares at Jun. 30, 2025 1,262,896      
Balance at Dec. 31, 2025 $ 203 98,583,686 (111,031,690) (12,447,801)
Balance, shares at Dec. 31, 2025 2,026,150      
Common stock issued pursuant to consulting agreement $ 2 514,283 514,285
Common stock issued pursuant to consulting agreement, shares 24,490      
Vested restricted stock granted to consultants 28,646 28,646
Vested restricted stock granted to employees 169,853 169,853
Vested restricted stock granted to employees, shares      
Net loss (7,742,597) (7,742,597)
Common stock and warrants issued in settlement of accrued compensation $ 20 2,589,560 2,589,580
Common stock and warrants issued in settlement of accrued compensation, shares 200,000      
Common stock issued in settlement of vendor obligation $ 13 1,356,607 1,356,620
Common stock issued in settlement of vendor obligation, shares 129,320      
Common stock issued as settlement and legal fees $ 1 51,999 52,000
Common stock issued as settlement and legal fees, shares 8,000      
Issuance of placement agent warrants in connection with convertible notes 416,965 416,965
Balance at Mar. 31, 2026 $ 239 103,711,599 (118,774,287) (15,062,449)
Balance, shares at Mar. 31, 2026 2,387,960      
Balance at Dec. 31, 2025 $ 203 98,583,686 (111,031,690) (12,447,801)
Balance, shares at Dec. 31, 2025 2,026,150      
Net loss       (26,105,822)
Balance at Jun. 30, 2026 $ 283 117,632,998 (137,137,512) (19,504,231)
Balance, shares at Jun. 30, 2026 2,836,484      
Balance at Mar. 31, 2026 $ 239 103,711,599 (118,774,287) (15,062,449)
Balance, shares at Mar. 31, 2026 2,387,960      
Common stock issued pursuant to consulting agreement $ 1 149,717 149,718
Common stock issued pursuant to consulting agreement, shares 14,085      
Vested restricted stock granted to employees 1,104,129 1,104,129
Vested restricted stock granted to employees, shares 8,929      
Net loss (18,363,225) (18,363,225)
Common stock issued in settlement of vendor obligation $ 10 644,990 645,000
Common stock issued in settlement of vendor obligation, shares 100,000      
Issuance of placement agent warrants in connection with convertible notes 2,685,666 2,685,666
Common stock issued in pursuant to exercise of warrants $ 20 11,011 11,031
Common stock issued in pursuant to exercise of warrants, shares 200,000      
Common stock issued pursuant to contract termination fees $ 13 766,379 766,392
Common stock issued pursuant to contract termination fees, shares 125,465      
Issuance of PIPE warrants in connection with convertible notes 10,047,930 10,047,930
Equity issuance costs   (1,488,423)   (1,488,423)
Effect of reverse stock split
Effect of reverse stock split, shares 45      
Balance at Jun. 30, 2026 $ 283 $ 117,632,998 $ (137,137,512) $ (19,504,231)
Balance, shares at Jun. 30, 2026 2,836,484